Search

Displaying results 1621 - 1630 of 8517 in total
  1. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]

  2. Drug

    MMDA

    go.drugbank.com/drugs/DB01442
    ExperimentalIllicit

    The effects of MMDA includes feelings of euphoria and warmth, as well as realistic closed-eye visuals. … It also acts as an entheogen and an entactogen. MMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg.

  3. Drug

    Asparaginase Escherichia coli

    go.drugbank.com/drugs/DB00023
    ApprovedInvestigational

    It is available as intramuscular or intravenous injections. … Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997].

  4. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    [L13988] It has also been investigated, by itself or together with [zoliflodacin], for the treatment of gonorrhea,[A203432, A203495] and was recently suggested as a possible treatment for liver-stage _ … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.

  5. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    Desmopressin, also known as 1-deamino-8-D-arginine vasopressin (DDAVP), is a synthetic analogue of the natural posterior pituitary hormone arginine vasopressin (AVP) [A275458, L56105]. … It was designed through two primary chemical modifications of the natural hormone: the deamination of 1-cysteine and the substitution of L-arginine with D-arginine at the 8th position [A31661, A275458]

  6. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.

  7. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  8. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated.

  9. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    [A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]

  10. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476]. … Proxibarbal is a derivative of barbiturates, which has been used to treat migraines.